| CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells L Jin, Y Tabe, S Konoplev, Y Xu, CE Leysath, H Lu, S Kimura, A Ohsaka, ... Molecular cancer therapeutics 7 (1), 48-58, 2008 | 253 | 2008 |
| Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia M Konopleva, T Tsao, P Ruvolo, I Stiouf, Z Estrov, CE Leysath, S Zhao, ... Blood, The Journal of the American Society of Hematology 99 (1), 326-335, 2002 | 222 | 2002 |
| The sub‐nanomolar binding of DNA–RNA hybrids by the single‐chain Fv fragment of antibody S9. 6 DD Phillips, DN Garboczi, K Singh, Z Hu, SH Leppla, CE Leysath Journal of Molecular Recognition 26 (8), 376-381, 2013 | 156 | 2013 |
| Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia M Milella, Z Estrov, SM Kornblau, BZ Carter, M Konopleva, A Tari, ... Blood, The Journal of the American Society of Hematology 99 (9), 3461-3464, 2002 | 155 | 2002 |
| Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). PA Morton, XT Fu, JA Stewart, KS Giacoletto, SL White, CE Leysath, ... The Journal of Immunology 156 (3), 1047-1054, 1996 | 139 | 1996 |
| A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2 JM Tremblay, J Mukherjee, CE Leysath, M Debatis, K Ofori, K Baldwin, ... Infection and immunity 81 (12), 4592-4603, 2013 | 103 | 2013 |
| A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model J Mukherjee, JM Tremblay, CE Leysath, K Ofori, K Baldwin, X Feng, ... PloS one 7 (1), e29941, 2012 | 100 | 2012 |
| Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival G Monaco, M Konopleva, M Munsell, C Leysath, RY Wang, CE Jackson, ... Stem Cells 22 (2), 188-201, 2004 | 60 | 2004 |
| Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors DD Phillips, RJ Fattah, D Crown, Y Zhang, S Liu, M Moayeri, ER Fischer, ... Journal of Biological Chemistry 288 (13), 9058-9065, 2013 | 50 | 2013 |
| Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen CE Leysath, AF Monzingo, JA Maynard, J Barnett, G Georgiou, BL Iverson, ... Journal of molecular biology 387 (3), 680-693, 2009 | 44 | 2009 |
| A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation … M Moayeri, CE Leysath, JM Tremblay, C Vrentas, D Crown, SH Leppla, ... Journal of Biological Chemistry 290 (10), 6584-6595, 2015 | 36 | 2015 |
| Engineering antibody fragments to fold in the absence of disulfide bonds MJ Seo, KJ Jeong, CE Leysath, AD Ellington, BL Iverson, G Georgiou Protein Science 18 (2), 259-267, 2009 | 36 | 2009 |
| Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins C Bachran, R Hasikova, CE Leysath, I Sastalla, Y Zhang, RJ Fattah, S Liu, ... Cell death & disease 5 (1), e1003-e1003, 2014 | 32 | 2014 |
| Mouse monoclonal antibodies to anthrax edema factor protect against infection CE Leysath, KH Chen, M Moayeri, D Crown, R Fattah, Z Chen, SR Das, ... Infection and immunity 79 (11), 4609-4616, 2011 | 30 | 2011 |
| Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection M Moayeri, D Crown, GS Jiao, S Kim, A Johnson, C Leysath, SH Leppla Antimicrobial agents and chemotherapy 57 (9), 4139-4145, 2013 | 29 | 2013 |
| Anthrax toxin protective antigen variants that selectively utilize either the CMG2 or TEM8 receptors for cellular uptake and tumor targeting KH Chen, S Liu, CE Leysath, S Miller-Randolph, Y Zhang, R Fattah, ... Journal of Biological Chemistry 291 (42), 22021-22029, 2016 | 26 | 2016 |
| Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex M Radjainia, JK Hyun, CE Leysath, SH Leppla, AK Mitra Proceedings of the National Academy of Sciences 107 (32), 14070-14074, 2010 | 20 | 2010 |
| Reductive methylation and mutation of an anthrax toxin fusion protein modulates its stability and cytotoxicity C Bachran, PK Gupta, S Bachran, CE Leysath, B Hoover, RJ Fattah, ... Scientific reports 4 (1), 1-8, 2014 | 17 | 2014 |
| Anthrax edema factor toxicity is strongly mediated by the N-end rule CE Leysath, DD Phillips, D Crown, RJ Fattah, M Moayeri, SH Leppla PLoS One 8 (8), e74474, 2013 | 14 | 2013 |
| Zeptomole per milliliter detection and quantification of edema factor in plasma by LC-MS/MS yields insights into toxemia and the progression of inhalation anthrax RC Lins, AE Boyer, Z Kuklenyik, AR Woolfitt, J Goldstein, AR Hoffmaster, ... Analytical and bioanalytical chemistry 411 (12), 2493-2509, 2019 | 11 | 2019 |
